Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Thornton

Pulmonary Disease Pinehurst, NC Medical Doctor

NPI 1265472773 CMS profile 239061

205 Page Rd, Pinehurst, NC 28374

Open in the dashboard

General payments

$9,479

503 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Thornton of Pinehurst, NC is reported in the CMS Open Payments database as having received $9,479 across 503 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,415 67
2024 General $1,762 81
2023 General $1,965 104
2022 General $1,138 56
2021 General $613 37
2020 General $588 43
2019 General $1,997 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Thornton
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to David Thornton were reported at $1,415. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year David Thornton Pulmonary Disease median Middle half National median
2019 $1,997 $377 $109–$1,340 $163
2020 $588 $230 $56–$907 $114
2021 $613 $269 $68–$1,072 $132
2022 $1,138 $390 $100–$1,457 $149
2023 $1,965 $419 $114–$1,659 $160
2024 $1,762 $476 $123–$1,818 $164
2025 $1,415 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $898 68 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $590 31 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $578 30 payments
  4. AstraZeneca Pharmaceuticals LP $576 35 payments
  5. Actelion Pharmaceuticals US, Inc. $570 29 payments
  6. Grifols USA, LLC $547 19 payments
  7. Jazz Pharmaceuticals Inc. $499 24 payments
  8. Mylan Specialty L.P. $448 23 payments
  9. Merck Sharp & Dohme Corporation $433 22 payments
  10. Amgen Inc. $382 23 payments
  11. Other $3,959 199 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,438 501 payments
  2. Education $41 2 payments
Products named General payments · program years 2019–2025
  1. OPSUMIT $608 31 payments
  2. Prolastin-C Liquid $533 18 payments
  3. TRELEGY ELLIPTA $473 38 payments
  4. XYWAV $391 18 payments
  5. GLASSIA $367 20 payments
  6. OFEV $303 17 payments
  7. INSPIRE $293 5 payments
  8. Arikayce $283 16 payments
  9. Yupelri $254 14 payments
  10. DUPIXENT $253 11 payments
  11. Other $7,314 419 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$316,278

Of which drugs: $71,595

Medicare patients

963

Average age 75

Services billed

8,158

516 women, 447 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 55%
Arthritis 55%
Ischemic heart disease 37%
Diabetes 34%
Chronic kidney disease 33%
Heart failure 32%
Depression 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 20 1,830 $178

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 40 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OFEV
$177 — —
TEZSPIRE
$105 — —
DUPIXENT
$102 — —
XYWAV
$95 — —
GLASSIA
$90 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 40 with Patron

Records

503 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record